

ongoing trials - trial from www.clinicaltrials.gov

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Code:
EUCTR2021-000713-17

Year: 2021 **Date:** October 2021

Author:

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Participants

Chronic Pseudomonas Aeruginosa Infection|Cystic Fibrosis - 18 Years and older (Adult, Older Adult)

Interventions

Drug: BX004-A|Drug: Placebo

Outcome measures

Safety and tolerability

<https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000713-17/NO/>

Keywords

YPT-01; Phage therapy; Anti-bacterial agents; pharmacological_intervention; Bacterial Infections; Infection; Inhalation OR nebulised; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections;